Fair value · Radiopharm Theranostics Ltd (RADX) · updated 2026-09-21 · from 20-F FY2025
Radiopharm Theranostics trades at $1.63. We are not reading assumptions out of that price: this is a depositary receipt and we cannot show whether its per-share figures are stated per ADS or per ordinary share, so these methods are withheld rather than shown at a scale we cannot verify.
Everything below is unaffected: the filed statements, the filing they came from, and RADX’s growth history are all as reported.
At least two methods need a usable value to draw a range with these inputs.
Range with preset inputs
No preset range for this company yet.
The two ranges are identical because every input sits on a preset.
We don’t tell you what RADX is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has RADX’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.
Discounted cash flow
N/A
This is a depositary receipt and we cannot show whether its per-share figures are stated per ADS or per ordinary share, so these methods are withheld rather than shown at a scale we cannot verify.
Preset inputs — revenue-driven DCF from the latest filing
Implied by today’s price
This is a depositary receipt and we cannot show whether its per-share figures are stated per ADS or per ordinary share, so these methods are withheld rather than shown at a scale we cannot verify.
Not solvable from the price — This is a depositary receipt and we cannot show whether its per-share figures are stated per ADS or per ordinary share, so these methods are withheld rather than shown at a scale we cannot verify. Showing preset inputs.
This method has no key input to read out of the price. The others below do, and you set them yourself: the growth matrix shows what RADX has actually filed, and the AI chat will reason it through with you.
Your inputs
Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.
Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.
-20.0%60.0%
How long stage-1 growth lasts.
1 yrs10 yrs
Slower growth after stage 1, before the terminal phase.
-20.0%30.0%
0 yrs10 yrs
Growth forever after the two stages. Above ~3% is rarely justified.
0.0%5.0%
The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.
